{"organizations": [], "uuid": "e56cf736d8377de5525a47ff25047f50f0c85179", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180418.html", "section_title": "Archive News &amp; Video for Wednesday, 18 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-calithera-biosciences-announces-fd/brief-calithera-biosciences-announces-fda-fast-track-designation-granted-to-cb-839-in-combination-with-cabozantinib-for-treatment-of-patients-with-advanced-renal-cell-carcinoma-idUSASC09W9A", "country": "US", "domain_rank": 408, "title": "BRIEF-Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 In Combination With Cabozantinib For Treatment Of Patients With Advanced Renal Cell Carcinoma", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.986, "site_type": "news", "published": "2018-04-18T19:25:00.000+03:00", "replies_count": 0, "uuid": "e56cf736d8377de5525a47ff25047f50f0c85179"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-calithera-biosciences-announces-fd/brief-calithera-biosciences-announces-fda-fast-track-designation-granted-to-cb-839-in-combination-with-cabozantinib-for-treatment-of-patients-with-advanced-renal-cell-carcinoma-idUSASC09W9A", "ord_in_thread": 0, "title": "BRIEF-Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 In Combination With Cabozantinib For Treatment Of Patients With Advanced Renal Cell Carcinoma", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "neutral"}, {"name": "calithera biosciences inc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 18 (Reuters) - Calithera Biosciences Inc:\n* CALITHERA BIOSCIENCES ANNOUNCES FDA FAST TRACK DESIGNATION GRANTED TO CB-839 IN COMBINATION WITH CABOZANTINIB FOR TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-18T19:25:00.000+03:00", "crawled": "2018-04-19T14:43:02.000+03:00", "highlightTitle": ""}